Vir Biotechnology (VIR) Financials

$4.76 +0.10 (+2.15%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$4.82 +0.07 (+1.37%)

As of 05/28/2025 07:59 PM Eastern

Annual Income Statements for Vir Biotechnology

This table shows Vir Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Income / (Loss) Attributable to Common Shareholders	-522	-615	516	529	-299	-175	-116	-70
Consolidated Net Income / (Loss)	-522	-615	516	529	-299	-175	-116	-70
Net Income / (Loss) Continuing Operations	-522	-615	516	529	-299	-175	-116	-70
Total Pre-Tax Income	-523	-628	754	550	-299	-175	-116	-81
Total Operating Income	-587	-684	833	421	-297	-178	-119	-81
Total Gross Profit	73	83	1,469	1,030	76	8.09	11	2.71
Total Revenue	74	86	1,616	1,095	76	8.09	11	2.71
Operating Revenue	74	86	1,616	1,095	76	8.09	11	2.71
Total Cost of Revenue	0.85	2.77	146	66	0.00	0.00	0.00	0.00
Operating Cost of Revenue	0.85	2.77	146	66	0.00	0.00	-	-
Total Operating Expenses	661	768	636	609	373	186	129	84
Selling, General & Admin Expense	119	174	162	161	71	38	29	22
Research & Development Expense	506	580	475	448	302	148	100	63
Restructuring Charge	35	14	0.00	-	-	-	-	-
Total Other Income / (Expense), net	64	56	-79	129	-1.63	3.45	2.33	0.72
Interest & Investment Income	72	87	28	0.44	-	-	-	0.64
Other Income / (Expense), net	-7.75	-31	-107	129	-4.47	-5.06	-0.21	0.08
Income Tax Expense	-1.15	-13	238	21	0.05	0.15	-0.48	-11
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-0.06	0.00	0.00	-	-	-	-
Basic Earnings per Share	($3.83)	($4.59)	$3.89	$4.07	($2.51)	($5.76)	($15.12)	($32.45)
Weighted Average Basic Shares Outstanding	136.25M	134.13M	132.61M	129.88M	119.16M	30.35M	7.67M	2.15M
Diluted Earnings per Share	($3.83)	($4.59)	$3.83	$3.96	($2.51)	($5.76)	($15.12)	($32.45)
Weighted Average Diluted Shares Outstanding	136.25M	134.13M	134.81M	133.44M	119.16M	30.35M	7.67M	2.15M
Weighted Average Basic & Diluted Shares Outstanding	137.14M	135.03M	133.53M	132.30M	119.16M	30.35M	7.67M	2.15M

This table shows Vir Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-121	-105	-214	-138	-65	-116	-163	-195	-141	-102	175
Consolidated Net Income / (Loss)	-121	-105	-214	-138	-65	-116	-163	-195	-141	-102	175
Net Income / (Loss) Continuing Operations	-121	-105	-214	-138	-65	-116	-163	-195	-141	-102	175
Total Pre-Tax Income	-121	-105	-214	-140	-65	-121	-167	-198	-143	-152	218
Total Operating Income	-140	-117	-231	-159	-80	-139	-187	-215	-143	-151	195
Total Gross Profit	3.03	12	2.33	3.02	56	16	2.60	3.78	61	43	352
Total Revenue	3.03	12	2.38	3.08	56	17	2.64	3.80	63	49	375
Operating Revenue	3.03	12	2.38	3.08	56	17	2.64	3.80	63	49	375
Total Cost of Revenue	0.00	0.68	0.05	0.05	0.06	0.80	0.04	0.02	1.91	6.00	22
Operating Cost of Revenue	0.00	0.68	0.05	0.05	0.06	0.80	0.04	0.02	1.91	6.00	22
Total Operating Expenses	143	129	234	162	136	155	189	219	204	194	157
Selling, General & Admin Expense	24	27	26	30	36	41	41	46	47	39	43
Research & Development Expense	119	106	195	105	100	109	145	168	158	155	114
Restructuring Charge	-0.01	-	13	26	-	-	3.37	5.37	-	-	-
Total Other Income / (Expense), net	19	12	18	19	15	18	20	18	0.18	-1.14	23
Interest & Investment Income	12	-	18	-	21	-	22	-	-	-	9.33
Other Income / (Expense), net	6.31	-1.68	0.24	-0.11	-6.20	-2.48	-1.83	-5.45	-21	-17	13
Income Tax Expense	0.02	-0.09	0.18	-1.51	0.28	-4.78	-3.21	-2.85	-2.23	-50	42
Basic Earnings per Share	($0.88)	($0.77)	($1.56)	($1.02)	($0.48)	($0.86)	($1.22)	($1.45)	($1.06)	($0.78)	$1.32
Weighted Average Basic Shares Outstanding	137.47M	136.25M	136.65M	136.23M	135.28M	134.13M	134.29M	134.06M	133.55M	132.61M	132.73M
Diluted Earnings per Share	($0.88)	($0.77)	($1.56)	($1.02)	($0.48)	($0.86)	($1.22)	($1.45)	($1.06)	($0.74)	$1.30
Weighted Average Diluted Shares Outstanding	137.47M	136.25M	136.65M	136.23M	135.28M	134.13M	134.29M	134.06M	133.55M	134.81M	134.96M
Weighted Average Basic & Diluted Shares Outstanding	138.24M	137.14M	137.72M	136.64M	136.06M	135.03M	134.52M	134.25M	133.98M	133.53M	133.12M

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Change in Cash & Equivalents	57	-607	505	-88	329	63	-130	175
Net Cash From Operating Activities	-446	-779	1,663	-48	-191	-130	-94	-66
Net Cash From Continuing Operating Activities	-446	-779	1,663	-48	-191	-130	-94	-66
Net Income / (Loss) Continuing Operations	-522	-615	516	529	-299	-175	-116	-70
Consolidated Net Income / (Loss)	-522	-615	516	529	-299	-175	-116	-70
Depreciation Expense	15	19	6.78	5.28	4.40	3.29	1.62	0.26
Amortization Expense	5.40	-8.71	-8.94	0.29	2.59	1.04	0.81	0.18
Non-Cash Adjustments To Reconcile Net Income	143	131	500	-61	33	24	7.35	9.10
Changes in Operating Assets and Liabilities, net	-87	-306	650	-521	68	17	12	-6.06
Net Cash From Investing Activities	499	165	-1,193	-141	-9.86	-256	-60	-30
Net Cash From Continuing Investing Activities	499	165	-1,193	-141	-9.86	-256	-60	-30
Purchase of Property, Plant & Equipment	-7.30	-22	-68	-22	-6.55	-8.94	-9.94	-2.74
Purchase of Investments	-1,235	-2,016	-1,477	-420	-404	-644	-123	0.00
Sale of Property, Plant & Equipment	3.37	0.00	0.00	-	0.00	0.00	0.03	0.00
Sale and/or Maturity of Investments	1,739	2,202	352	301	400	397	73	0.00
Net Cash From Financing Activities	4.39	7.48	35	100	529	449	25	271
Net Cash From Continuing Financing Activities	4.39	7.48	35	100	529	449	25	271
Repayment of Debt	-0.17	-0.29	-0.26	-	-	3.27	0.00	0.00
Issuance of Common Equity	3.76	4.28	32	88	530	126	0.00	0.00
Other Financing Activities, net	0.79	3.48	3.34	13	-0.44	2.23	11	0.00
Cash Income Taxes Paid	0.79	2.68	-252	0.00	0.00	-	-	-

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	49	54	-53	137	-81	-211	-215	-156	-25	-116	-543
Net Cash From Operating Activities	-78	-88	-171	-78	-109	-108	-156	-389	-126	35	118
Net Cash From Continuing Operating Activities	-78	-88	-171	-78	-109	-108	-156	-389	-126	35	118
Net Income / (Loss) Continuing Operations	-121	-105	-214	-138	-65	-116	-163	-195	-141	-102	175
Consolidated Net Income / (Loss)	-121	-105	-214	-138	-65	-116	-163	-195	-141	-102	175
Depreciation Expense	2.87	2.89	2.90	4.26	4.52	4.48	4.59	4.75	5.64	2.35	1.55
Amortization Expense	4.09	2.17	0.35	2.64	0.24	1.35	2.31	-3.00	-9.37	-8.03	-2.91
Non-Cash Adjustments To Reconcile Net Income	9.83	32	21	56	33	35	31	57	7.97	28	-1.06
Changes in Operating Assets and Liabilities, net	26	-20	18	-2.54	-82	-33	-30	-253	11	114	-55
Net Cash From Investing Activities	127	141	119	212	28	-105	-59	230	98	-153	-663
Net Cash From Continuing Investing Activities	127	141	119	212	28	-105	-59	230	98	-153	-663
Purchase of Property, Plant & Equipment	-1.63	-2.41	-2.36	-0.67	-1.87	-1.54	-3.71	-9.46	-6.87	-13	-19
Purchase of Investments	-174	-161	-240	-271	-563	-819	-503	-310	-385	-407	-728
Sale of Property, Plant & Equipment	0.28	2.46	0.01	0.38	0.53	-	-	-	0.00	-0.02	0.01
Sale and/or Maturity of Investments	302	301	362	483	593	716	448	550	489	267	85
Net Cash From Financing Activities	0.60	1.26	0.03	2.94	0.15	1.68	0.28	3.18	2.34	2.01	1.99
Net Cash From Continuing Financing Activities	0.60	1.26	0.03	2.94	0.15	1.68	0.28	3.18	2.34	2.01	1.99
Other Financing Activities, net	0.60	0.27	0.03	0.34	0.15	0.29	0.28	0.67	2.24	1.12	1.99

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Assets	1,399	1,919	2,802	1,954	919	512	192
Total Current Assets	1,042	1,588	2,519	1,563	772	403	118
Cash & Equivalents	223	242	849	348	437	109	48
Restricted Cash	89	13	13	8.59	7.99	6.18	11
Short-Term Investments	682	1,281	1,553	360	300	274	51
Prepaid Expenses	48	53	104	73	28	13	8.58
Plant, Property, & Equipment, net	63	96	106	43	18	16	12
Total Noncurrent Assets	293	235	177	349	128	93	62
Long-Term Investments	190	105	24	201	0.00	24	0.00
Goodwill	17	17	17	17	17	17	17
Intangible Assets	8.12	23	33	33	34	36	37
Other Noncurrent Operating Assets	72	84	97	90	71	8.55	6.67
Other Noncurrent Nonoperating Assets	6.36	6.45	6.66	7.01	6.92	7.30	1.00
Total Liabilities & Shareholders' Equity	1,399	1,919	2,802	1,954	919	512	192
Total Liabilities	248	329	724	522	202	88	62
Total Current Liabilities	120	175	511	341	99	59	40
Short-Term Debt	16	0.00	-	0.00	11	8.20	0.00
Accounts Payable	5.08	6.33	6.42	6.52	5.08	5.88	6.47
Accrued Expenses	86	104	489	237	77	26	15
Current Deferred Revenue	13	65	16	98	6.45	6.18	8.76
Total Noncurrent Liabilities	129	153	213	181	103	29	22
Other Noncurrent Operating Liabilities	129	153	160	159	96	13	11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,150	1,590	2,078	1,432	717	424	-179
Total Preferred & Common Equity	1,150	1,590	2,078	1,432	717	424	-179
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,150	1,590	2,078	1,432	717	424	-179
Common Stock	1,912	1,829	1,710	1,572	1,385	793	15
Retained Earnings	-760	-238	377	-139	-667	-369	-194
Accumulated Other Comprehensive Income / (Loss)	-1.72	-0.82	-9.12	-1.10	-1.28	-0.60	-0.01

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,308	1,498	1,670	1,794	2,045	2,244	2,666	2,696
Total Current Assets	932	1,047	1,206	1,213	1,769	1,946	2,359	2,414
Cash & Equivalents	274	168	297	161	452	667	825	964
Restricted Cash	88	90	14	13	13	13	11	13
Short-Term Investments	528	746	854	989	1,244	1,180	1,425	1,360
Prepaid Expenses	42	43	41	50	59	86	98	54
Plant, Property, & Equipment, net	62	65	66	92	99	104	104	100
Total Noncurrent Assets	314	386	398	488	176	193	204	182
Long-Term Investments	218	271	280	360	40	52	49	34
Goodwill	17	17	17	17	17	17	17	17
Intangible Assets	8.07	19	19	22	25	26	33	33
Other Noncurrent Operating Assets	64	72	76	83	87	92	98	91
Other Noncurrent Nonoperating Assets	6.27	6.38	6.37	6.43	7.06	6.74	6.74	7.28
Total Liabilities & Shareholders' Equity	1,308	1,498	1,670	1,794	2,045	2,244	2,666	2,696
Total Liabilities	264	258	236	247	370	434	695	546
Total Current Liabilities	137	117	96	94	165	226	485	308
Short-Term Debt	18	-	-	-	-	-	-	-
Accounts Payable	3.73	7.31	4.39	7.11	3.63	12	12	2.72
Accrued Expenses	104	95	75	72	146	198	456	283
Current Deferred Revenue	12	15	17	15	15	16	17	23
Total Noncurrent Liabilities	127	140	139	153	205	208	210	238
Other Noncurrent Operating Liabilities	127	140	139	151	152	155	153	165
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,044	1,241	1,434	1,547	1,675	1,810	1,971	2,150
Total Preferred & Common Equity	1,044	1,241	1,434	1,547	1,675	1,810	1,971	2,150
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,044	1,241	1,434	1,547	1,675	1,810	1,971	2,150
Common Stock	1,927	1,895	1,878	1,853	1,799	1,772	1,738	1,683
Retained Earnings	-881	-655	-441	-303	-122	42	236	479
Accumulated Other Comprehensive Income / (Loss)	-1.98	1.13	-2.88	-2.40	-1.90	-2.90	-3.22	-12

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	-13.90%	-94.67%	47.51%	1,334.39%	843.86%	-24.16%	293.94%	0.00%
EBITDA Growth	18.38%	-197.29%	30.47%	288.46%	-64.78%	-53.42%	-43.83%	0.00%
EBIT Growth	16.82%	-198.48%	32.19%	282.24%	-64.69%	-53.94%	-46.05%	0.00%
NOPAT Growth	14.20%	-184.08%	40.84%	294.58%	-66.86%	-49.95%	-45.64%	0.00%
Net Income Growth	15.14%	-219.25%	-2.41%	276.98%	-70.98%	-50.74%	-65.90%	0.00%
EPS Growth	16.56%	-219.84%	-3.28%	257.77%	56.42%	61.90%	53.41%	0.00%
Operating Cash Flow Growth	42.69%	-146.82%	3,595.04%	75.08%	-47.29%	-37.77%	-41.75%	0.00%
Free Cash Flow Firm Growth	43.80%	-154.66%	1,241.11%	26.71%	-50.45%	-10.48%	0.00%	0.00%
Invested Capital Growth	56.85%	84.44%	-172.49%	2,183.45%	-322.41%	-47.37%	0.00%	0.00%
Revenue Q/Q Growth	-5.61%	-27.46%	-32.08%	285.18%	1.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	3.67%	5.10%	-49.91%	674.37%	-15.57%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	3.67%	3.55%	-49.56%	639.22%	-15.28%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	3.59%	1.65%	-53.46%	322.77%	-17.69%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	2.13%	-2.39%	-54.86%	616.60%	-16.31%	0.00%	0.00%	0.00%
EPS Q/Q Growth	2.30%	-2.68%	-55.31%	540.00%	-162.44%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	4.35%	-22.50%	1.68%	65.35%	-29.21%	-7.80%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	4.91%	-20.18%	-1.61%	29.04%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	40.16%	29.72%	-46.37%	6,607.20%	-439.99%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	98.86%	96.79%	90.94%	93.99%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-774.82%	-817.40%	44.81%	50.66%	-385.58%	-2,208.65%	-1,091.83%	-2,990.47%
Operating Margin	-791.27%	-794.04%	51.56%	38.41%	-388.88%	-2,199.72%	-1,112.60%	-3,009.49%
EBIT Margin	-801.72%	-829.87%	44.94%	50.15%	-394.73%	-2,262.27%	-1,114.59%	-3,006.43%
Profit (Net Income) Margin	-703.40%	-713.76%	31.92%	48.25%	-391.09%	-2,158.98%	-1,086.28%	-2,579.47%
Tax Burden Percent	99.78%	97.92%	68.39%	96.14%	100.02%	100.09%	99.59%	86.48%
Interest Burden Percent	87.93%	87.84%	103.87%	100.08%	99.06%	95.35%	97.86%	99.22%
Effective Tax Rate	0.00%	0.00%	31.61%	3.86%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	817.53%	167.71%	0.00%	-785.73%	-799.77%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	820.73%	152.82%	0.00%	-766.54%	-739.69%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	-788.14%	-118.51%	0.00%	722.66%	621.43%	0.00%
Return on Equity (ROE)	-38.09%	-33.54%	29.39%	49.20%	-52.36%	-63.07%	-178.34%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-24.97%	0.00%	-723.66%	-999.77%	0.00%
Operating Return on Assets (OROA)	-35.86%	-30.30%	30.54%	38.24%	-42.14%	-52.02%	-62.06%	0.00%
Return on Assets (ROA)	-31.46%	-26.06%	21.69%	36.80%	-41.75%	-49.65%	-60.48%	0.00%
Return on Common Equity (ROCE)	-38.09%	-33.54%	29.39%	49.20%	-52.36%	-27.87%	245.88%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-45.37%	-38.68%	24.82%	36.92%	-41.66%	-41.20%	64.68%	0.00%
Net Operating Profit after Tax (NOPAT)	-411	-479	570	405	-208	-125	-83	-57
NOPAT Margin	-553.89%	-555.83%	35.26%	36.93%	-272.22%	-1,539.80%	-778.82%	-2,106.64%
Net Nonoperating Expense Percent (NNEP)	-7.86%	-6.65%	-3.20%	14.89%	-15.73%	-19.19%	-60.08%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-35.24%	-30.12%	27.42%	-	-	-	-	-
Cost of Revenue to Revenue	1.14%	3.21%	9.06%	6.01%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	160.41%	202.41%	10.01%	14.68%	92.89%	464.69%	273.07%	801.07%
R&D to Revenue	682.57%	672.69%	29.38%	40.90%	395.99%	1,835.03%	939.53%	2,308.42%
Operating Expenses to Revenue	890.14%	890.83%	39.39%	55.58%	488.88%	2,299.72%	1,212.60%	3,109.49%
Earnings before Interest and Taxes (EBIT)	-595	-715	726	549	-301	-183	-119	-81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-575	-704	724	555	-294	-179	-116	-81
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.88	0.85	1.62	3.83	4.76	3.25	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.90	0.87	1.66	3.97	5.12	3.71	0.00	0.00
Price to Revenue (P/Rev)	13.62	15.70	2.09	5.00	44.67	170.46	13.39	52.75
Price to Earnings (P/E)	0.00	0.00	6.53	10.37	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	15.31%	9.65%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	9.00	0.00	89.03	16.50	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.58	4.16	35.06	120.32	32.13	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	1.29	8.22	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	1.28	8.30	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	1.63	11.28	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.56	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.00	0.00	0.00	0.01	0.02	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.03	-1.12	-0.96	-0.78	-1.01	-0.94	-0.84	0.00
Leverage Ratio	1.21	1.29	1.36	1.34	1.25	1.27	1.47	0.00
Compound Leverage Factor	1.06	1.13	1.41	1.34	1.24	1.21	1.44	0.00
Debt to Total Capital	1.38%	0.00%	0.00%	0.00%	1.46%	1.90%	0.00%	0.00%
Short-Term Debt to Total Capital	1.38%	0.00%	0.00%	0.00%	1.46%	1.90%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	237.87%	0.00%
Common Equity to Total Capital	98.62%	100.00%	100.00%	100.00%	98.54%	98.10%	-137.87%	0.00%
Debt to EBITDA	-0.03	0.00	0.00	0.00	-0.04	-0.05	0.00	0.00
Net Debt to EBITDA	2.03	0.00	0.00	0.00	2.49	2.27	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.04	0.00	0.00	0.00	-0.05	-0.07	0.00	0.00
Net Debt to NOPAT	2.84	0.00	0.00	0.00	3.53	3.26	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.12	1.99	5.27	8.43	9.00	8.02	-1.53	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	55.81%	237.87%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	8.71	9.05	4.93	4.58	7.80	6.81	2.95	0.00
Quick Ratio	7.57	8.68	4.70	4.34	7.44	6.48	2.47	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-444	-789	1,444	-127	-173	-115	-104	0.00
Operating Cash Flow to CapEx	-11,360.45%	-3,610.00%	2,445.74%	-218.13%	-2,915.57%	-1,450.02%	-949.51%	-2,420.90%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.04	0.68	0.76	0.11	0.02	0.06	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.93	0.85	21.77	36.05	4.46	0.57	0.87	0.00
Accounts Payable Turnover	0.15	0.43	22.61	11.36	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	2,465.37	841.94	16.14	32.14	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-2,465.37	-841.94	-16.14	-32.14	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	-25	-57	-367	507	-24	11	21	0.00
Invested Capital Turnover	-1.81	-0.41	23.19	4.54	-11.41	0.51	1.03	0.00
Increase / (Decrease) in Invested Capital	32	310	-874	531	-35	-9.84	21	0.00
Enterprise Value (EV)	-158	-288	931	4,562	2,677	974	343	0.00
Market Capitalization	1,011	1,353	3,369	5,480	3,411	1,379	143	143
Book Value per Share	$8.35	$11.82	$15.61	$10.94	$5.63	$3.87	($23.37)	$0.00
Tangible Book Value per Share	$8.17	$11.53	$15.24	$10.56	$5.23	$3.39	($30.40)	$0.00
Total Capital	1,166	1,590	2,078	1,432	727	432	130	0.00
Total Debt	16	0.00	0.00	0.00	11	8.20	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,169	-1,641	-2,439	-918	-734	-406	-109	0.00
Capital Expenditures (CapEx)	3.93	22	68	22	6.55	8.94	9.91	2.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-56	-123	-407	505	-61	-38	-31	0.00
Debt-free Net Working Capital (DFNWC)	939	1,413	2,008	1,222	684	352	78	0.00
Net Working Capital (NWC)	923	1,413	2,008	1,222	673	344	78	0.00
Net Nonoperating Expense (NNE)	111	136	54	-124	91	50	33	13
Net Nonoperating Obligations (NNO)	-1,175	-1,647	-2,445	-925	-741	-413	-109	0.00
Total Depreciation and Amortization (D&A)	20	11	-2.16	5.57	6.99	4.34	2.43	0.43
Debt-free, Cash-free Net Working Capital to Revenue	-75.30%	-142.56%	-25.17%	46.09%	-79.81%	-465.06%	-293.67%	0.00%
Debt-free Net Working Capital to Revenue	1,265.22%	1,639.38%	124.28%	111.52%	895.53%	4,350.38%	729.99%	0.00%
Net Working Capital to Revenue	1,243.58%	1,639.38%	124.28%	111.52%	881.65%	4,249.03%	729.99%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.83)	($4.59)	$3.89	$4.07	($2.51)	($5.76)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	136.25M	134.13M	132.61M	129.88M	127.84M	109.80M	0.00	0.00
Adjusted Diluted Earnings per Share	($3.83)	($4.59)	$3.83	$3.96	($2.51)	($5.76)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	136.25M	134.13M	134.81M	133.44M	127.84M	109.80M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($2.51)	($5.76)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	137.14M	135.03M	133.53M	132.30M	119.16M	30.35M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-387	-470	570	405	-208	-125	-83	-57
Normalized NOPAT Margin	-520.88%	-544.82%	35.26%	36.93%	-272.22%	-1,539.80%	-778.82%	-2,106.64%
Pre Tax Income Margin	-704.95%	-728.93%	46.68%	50.19%	-391.02%	-2,157.08%	-1,090.78%	-2,982.87%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-94.62%	-26.29%	-9.81%	-19.02%	-10.45%	-66.03%	-99.30%	109.35%	-94.89%	-93.92%	261.49%
EBITDA Growth	-54.89%	16.13%	-25.41%	30.63%	51.54%	21.80%	-187.74%	6.32%	-118.20%	-131.67%	85.49%
EBIT Growth	-54.42%	16.02%	-22.54%	28.06%	47.55%	15.68%	-190.48%	6.48%	-117.85%	-130.75%	88.17%
NOPAT Growth	-74.26%	15.73%	-23.87%	26.28%	44.14%	7.63%	-183.27%	4.46%	-117.60%	-119.15%	394.94%
Net Income Growth	-85.31%	9.82%	-30.78%	28.95%	53.69%	-14.14%	-193.21%	-154.63%	-127.18%	-119.34%	58.76%
EPS Growth	-83.33%	10.47%	-27.87%	29.66%	54.72%	-16.22%	-193.85%	-150.00%	-127.53%	-118.50%	58.54%
Operating Cash Flow Growth	28.59%	18.80%	-10.04%	80.00%	13.03%	-407.26%	-232.17%	-140.54%	-122.87%	356.48%	211.42%
Free Cash Flow Firm Growth	93.65%	71.90%	32.73%	49.78%	-271.00%	-153.01%	-175.06%	-618.49%	-50.55%	3,924.14%	901.25%
Invested Capital Growth	-392.21%	56.85%	49.32%	83.84%	105.23%	84.44%	67.59%	69.82%	0.00%	-172.49%	-3,122.79%
Revenue Q/Q Growth	-75.50%	419.92%	-22.60%	-94.55%	235.83%	536.11%	-30.50%	-93.97%	27.42%	-86.81%	1,021.90%
EBITDA Q/Q Growth	-10.99%	50.06%	-50.04%	-86.24%	39.90%	25.32%	17.01%	-30.12%	3.03%	-183.80%	188.60%
EBIT Q/Q Growth	-12.13%	48.57%	-45.57%	-83.97%	39.02%	24.96%	14.54%	-34.13%	1.98%	-180.52%	188.33%
NOPAT Q/Q Growth	-19.12%	49.35%	-45.81%	-98.09%	42.39%	25.55%	13.22%	-50.09%	4.74%	-167.11%	199.57%
Net Income Q/Q Growth	-15.66%	51.06%	-54.44%	-111.99%	43.71%	29.03%	16.10%	-38.18%	-38.73%	-157.96%	329.19%
EPS Q/Q Growth	-14.29%	50.64%	-52.94%	-112.50%	44.19%	29.51%	15.86%	-36.79%	-43.24%	-156.92%	324.14%
Operating Cash Flow Q/Q Growth	10.86%	48.89%	-120.28%	28.84%	-1.36%	30.74%	59.97%	-209.46%	-458.09%	-70.21%	-87.72%
Free Cash Flow Firm Q/Q Growth	76.71%	43.32%	0.40%	51.74%	-3.15%	-35.68%	25.64%	-264.33%	-68.02%	92.10%	413.66%
Invested Capital Q/Q Growth	-114.49%	40.16%	-132.91%	-197.75%	131.67%	29.72%	25.71%	68.37%	5.77%	-46.37%	30.82%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	94.47%	97.90%	98.31%	99.90%	95.25%	98.56%	99.42%	96.97%	87.86%	94.06%
EBITDA Margin	-4,164.94%	-919.46%	-9,572.14%	-4,937.85%	-144.61%	-808.14%	-6,883.74%	-5,764.87%	-267.20%	-351.11%	55.27%
Operating Margin	-4,602.47%	-946.74%	-9,718.66%	-5,158.70%	-142.05%	-828.12%	-7,075.86%	-5,667.26%	-227.73%	-304.60%	52.05%
EBIT Margin	-4,394.36%	-960.30%	-9,708.70%	-5,162.15%	-153.05%	-842.87%	-7,145.02%	-5,810.88%	-261.28%	-339.63%	55.64%
Profit (Net Income) Margin	-3,989.61%	-845.23%	-8,979.71%	-4,500.10%	-115.79%	-690.85%	-6,192.23%	-5,129.71%	-223.89%	-205.63%	46.81%
Tax Burden Percent	100.01%	99.92%	100.08%	98.92%	100.42%	96.04%	98.07%	98.56%	98.44%	67.00%	80.52%
Interest Burden Percent	90.78%	88.09%	92.41%	88.13%	75.33%	85.34%	88.37%	89.57%	87.05%	90.36%	104.48%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	19.48%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,943.76%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,943.98%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4,747.66%	0.00%
Return on Equity (ROE)	-44.59%	-38.09%	-36.58%	-29.78%	-30.67%	-33.54%	-31.41%	-13.93%	-7.29%	-196.10%	75.52%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-4,412.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-59.11%	-42.95%	-430.84%	-208.09%	-5.46%	-30.77%	-358.10%	-1,172.77%	-43.74%	-230.75%	67.78%
Return on Assets (ROA)	-53.67%	-37.81%	-398.49%	-181.40%	-4.13%	-25.22%	-310.35%	-1,035.30%	-37.48%	-139.71%	57.02%
Return on Common Equity (ROCE)	-44.59%	-38.09%	-36.58%	-29.78%	-30.67%	-33.54%	-31.41%	-13.93%	-7.29%	-196.10%	75.52%
Return on Equity Simple (ROE_SIMPLE)	-55.34%	0.00%	-42.99%	-33.69%	-34.86%	0.00%	-35.86%	-14.47%	-7.29%	0.00%	53.15%
Net Operating Profit after Tax (NOPAT)	-98	-82	-162	-111	-56	-97	-131	-151	-100	-105	157
NOPAT Margin	-3,221.73%	-662.72%	-6,803.06%	-3,611.09%	-99.43%	-579.68%	-4,953.10%	-3,967.08%	-159.41%	-213.22%	41.91%
Net Nonoperating Expense Percent (NNEP)	-1.77%	-1.60%	-3.41%	-1.62%	-0.48%	-0.91%	-1.57%	-2.09%	-3.50%	0.22%	1.12%
Return On Investment Capital (ROIC_SIMPLE)	-9.20%	-7.03%	-	-	-	-6.12%	-	-	-	-5.07%	-
Cost of Revenue to Revenue	0.00%	5.53%	2.10%	1.69%	0.10%	4.75%	1.44%	0.58%	3.03%	12.14%	5.94%
SG&A Expenses to Revenue	789.71%	216.17%	1,081.68%	984.23%	64.34%	245.54%	1,551.08%	1,198.63%	74.30%	78.41%	11.53%
R&D to Revenue	3,913.09%	857.31%	8,200.76%	3,418.31%	177.60%	649.11%	5,495.57%	4,426.73%	250.40%	314.05%	30.48%
Operating Expenses to Revenue	4,702.47%	1,041.22%	9,816.55%	5,257.01%	241.94%	923.36%	7,174.42%	5,766.68%	324.70%	392.46%	42.01%
Earnings before Interest and Taxes (EBIT)	-133	-119	-231	-159	-86	-141	-189	-221	-164	-168	208
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-126	-114	-228	-152	-82	-136	-182	-219	-168	-173	207
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.85	0.88	0.82	0.84	0.88	0.85	0.75	1.82	1.58	1.62	1.19
Price to Tangible Book Value (P/TBV)	0.87	0.90	0.85	0.87	0.90	0.87	0.77	1.86	1.62	1.66	1.22
Price to Revenue (P/Rev)	42.60	13.62	13.02	15.35	17.12	15.70	10.59	6.70	6.96	2.09	1.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.53	2.24
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	15.31%	44.68%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.80	1.79	0.58	0.08
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.29	0.13
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.28	0.13
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.63	0.15
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.56	0.11
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.68	0.64	0.13
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-1.03	-1.04	-1.04	-1.09	-1.12	-1.09	-1.13	-1.18	-0.96	-1.09
Leverage Ratio	1.20	1.21	1.22	1.21	1.27	1.29	1.24	1.29	1.35	1.36	1.29
Compound Leverage Factor	1.09	1.07	1.12	1.06	0.96	1.10	1.10	1.16	1.18	1.22	1.35
Debt to Total Capital	1.65%	1.38%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	1.65%	1.38%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.35%	98.62%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.03	-0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.76	2.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.04	-0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.41	2.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.49	2.25	2.06	3.24	3.71	2.98	2.65	5.39	3.61	4.22	5.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.79	8.71	8.94	12.51	12.90	9.05	10.72	8.63	4.86	4.93	7.83
Quick Ratio	5.84	7.57	7.81	11.94	12.22	8.68	10.28	8.19	4.64	4.70	7.54
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27	-115	-202	-203	-420	-407	-300	-404	246	769	400
Operating Cash Flow to CapEx	-5,794.96%	0.00%	-7,293.92%	-27,124.39%	-8,169.53%	-7,031.07%	-4,195.72%	-4,115.97%	-1,831.69%	278.87%	621.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.04	0.04	0.04	0.04	0.04	0.05	0.20	0.17	0.68	1.22
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.27	0.93	0.96	0.93	0.81	0.85	1.19	5.19	4.30	21.77	37.52
Accounts Payable Turnover	0.15	0.15	0.18	0.11	0.10	0.43	2.51	2.63	4.78	22.61	56.78
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	2,516.69	2,465.37	2,080.39	3,228.15	3,833.69	841.94	145.51	138.97	76.35	16.14	6.43
Cash Conversion Cycle (CCC)	-2,516.69	-2,465.37	-2,080.39	-3,228.15	-3,833.69	-841.94	-145.51	-138.97	-76.35	-16.14	-6.43
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-53	-25	-41	-18	18	-57	-81	-109	-346	-367	-251
Invested Capital Turnover	-1.20	-1.81	-1.28	-1.24	-0.49	-0.41	-0.72	-2.08	-2.58	23.19	-18.39
Increase / (Decrease) in Invested Capital	-71	32	40	92	364	310	170	253	-346	-874	-243
Enterprise Value (EV)	-202	-158	-252	-234	-160	-288	-491	1,373	797	931	187
Market Capitalization	889	1,011	1,023	1,211	1,363	1,353	1,258	3,286	3,107	3,369	2,557
Book Value per Share	$7.61	$8.35	$9.08	$10.54	$11.44	$11.82	$12.48	$13.51	$14.76	$15.61	$16.21
Tangible Book Value per Share	$7.43	$8.17	$8.82	$10.27	$11.15	$11.53	$12.16	$13.19	$14.39	$15.24	$15.83
Total Capital	1,061	1,166	1,241	1,434	1,547	1,590	1,675	1,810	1,971	2,078	2,150
Total Debt	18	16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,090	-1,169	-1,276	-1,445	-1,523	-1,641	-1,749	-1,913	-2,310	-2,439	-2,371
Capital Expenditures (CapEx)	1.35	-0.05	2.35	0.29	1.34	1.54	3.71	9.46	6.87	13	19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-77	-56	-74	-56	-44	-123	-106	-140	-388	-407	-231
Debt-free Net Working Capital (DFNWC)	812	939	930	1,109	1,119	1,413	1,604	1,721	1,873	2,008	2,105
Net Working Capital (NWC)	795	923	930	1,109	1,119	1,413	1,604	1,721	1,873	2,008	2,105
Net Nonoperating Expense (NNE)	23	23	52	27	9.22	19	33	44	41	-3.75	-18
Net Nonoperating Obligations (NNO)	-1,097	-1,175	-1,282	-1,451	-1,529	-1,647	-1,756	-1,920	-2,317	-2,445	-2,401
Total Depreciation and Amortization (D&A)	6.96	5.05	3.25	6.90	4.76	5.83	6.90	1.75	-3.73	-5.68	-1.37
Debt-free, Cash-free Net Working Capital to Revenue	-370.99%	-75.30%	-94.22%	-70.59%	-55.36%	-142.56%	-88.90%	-28.51%	-86.87%	-25.17%	-9.72%
Debt-free Net Working Capital to Revenue	3,894.45%	1,265.22%	1,182.93%	1,406.40%	1,405.83%	1,639.38%	1,350.24%	350.65%	419.76%	124.28%	88.49%
Net Working Capital to Revenue	3,810.56%	1,243.58%	1,182.93%	1,406.40%	1,405.83%	1,639.38%	1,350.24%	350.65%	419.76%	124.28%	88.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.88)	($0.77)	($1.56)	($1.02)	($0.48)	($0.86)	($1.22)	($1.45)	($1.06)	($0.78)	$1.32
Adjusted Weighted Average Basic Shares Outstanding	137.47M	136.25M	136.65M	136.23M	135.28M	134.13M	134.29M	134.06M	133.55M	132.61M	132.73M
Adjusted Diluted Earnings per Share	($0.88)	($0.77)	($1.56)	($1.02)	($0.48)	($0.86)	($1.22)	($1.45)	($1.06)	($0.74)	$1.30
Adjusted Weighted Average Diluted Shares Outstanding	137.47M	136.25M	136.65M	136.23M	135.28M	134.13M	134.29M	134.06M	133.55M	134.81M	134.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	138.24M	137.14M	137.72M	136.64M	136.06M	135.03M	134.52M	134.25M	133.98M	133.53M	133.12M
Normalized Net Operating Profit after Tax (NOPAT)	-98	-82	-153	-93	-56	-97	-128	-147	-100	-105	157
Normalized NOPAT Margin	-3,221.96%	-662.72%	-6,429.18%	-3,012.96%	-99.43%	-579.68%	-4,863.66%	-3,868.16%	-159.41%	-213.22%	41.91%
Pre Tax Income Margin	-3,989.08%	-845.93%	-8,972.27%	-4,549.27%	-115.30%	-719.35%	-6,313.98%	-5,204.71%	-227.44%	-306.90%	58.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.02%	-0.04%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.02%	-0.04%	0.00%	0.00%	0.00%

Frequently Asked Questions About Vir Biotechnology's Financials

When does Vir Biotechnology's financial year end?

According to the most recent income statement we have on file, Vir Biotechnology's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Vir Biotechnology's net income changed over the last 7 years?

Vir Biotechnology's net income appears to be on an upward trend, with a most recent value of -$521.96 million in 2024, rising from -$69.85 million in 2017. The previous period was -$615.12 million in 2023. See where experts think Vir Biotechnology is headed by visiting Vir Biotechnology's forecast page.

What is Vir Biotechnology's operating income?

Vir Biotechnology's total operating income in 2024 was -$587.17 million, based on the following breakdown:

Total Gross Profit: $73.36 million
Total Operating Expenses: $660.53 million

How has Vir Biotechnology revenue changed over the last 7 years?

Over the last 7 years, Vir Biotechnology's total revenue changed from $2.71 million in 2017 to $74.21 million in 2024, a change of 2,640.2%.

How much debt does Vir Biotechnology have?

Vir Biotechnology's total liabilities were at $248.43 million at the end of 2024, a 24.4% decrease from 2023, and a 303.1% increase since 2018.

How much cash does Vir Biotechnology have?

In the past 6 years, Vir Biotechnology's cash and equivalents has ranged from $47.60 million in 2018 to $848.63 million in 2022, and is currently $222.95 million as of their latest financial filing in 2024.

How has Vir Biotechnology's book value per share changed over the last 7 years?

Over the last 7 years, Vir Biotechnology's book value per share changed from 0.00 in 2017 to 8.35 in 2024, a change of 835.3%.

Related Companies

This page (NASDAQ:VIR) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Financials

Frequently Asked Questions About Vir Biotechnology's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Financials

Annual Income Statements for Vir Biotechnology

Quarterly Income Statements for Vir Biotechnology

Annual Cash Flow Statements for Vir Biotechnology

Quarterly Cash Flow Statements for Vir Biotechnology

Annual Balance Sheets for Vir Biotechnology

Quarterly Balance Sheets for Vir Biotechnology

Annual Metrics And Ratios for Vir Biotechnology

Quarterly Metrics And Ratios for Vir Biotechnology

Frequently Asked Questions About Vir Biotechnology's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools